anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Systemic sclerosis (SSc) is a multisystem connective tissue disease. Skin fibrosis, the hallmark of this disease, is defined as the excess deposition and accumulation of extracellular matrix, mainly type 1 collagen, in the dermis. SLC39A7 is an intracellular zinc transporter that plays a unique role in connective tissue formation. Therefore, we investigated the expression and role of SLC39A7 in SSc. Using immunohistochemical staining we demonstrated the overexpression of SLC39A7 in the skin of SSc patients. Quantitative real-time PCR and western blot data analysis showed that both SLC39A7 mRNA and protein levels were significantly upregulated in dermal fibroblasts from SSc patients compared to healthy controls. We used the shRNA lentiviral particle transduction system to stably knockdown the expression of SLC39A7 in SSc fibroblasts. The results showed that knockdown of SLC39A7 suppressed the production of type 1 collagen. These findings provide evidence that SLC39A7 is involved in the pathogenesis of SSc and that SLC39A7 plays a positive role in its progression.
Music therapy by a certified music therapist will be delivered to infants over a period of 5 days. There will be two periods of data collection each day, one in the morning and one in the afternoon. Each baby will receive music therapy during one of these time points, with each baby serving as their own control during the second timepoint.
Sarcopenia is related to disease severity in chronic kidney disease (CKD) patients; however, its pathophysiology remains poorly known. We investigated the associations of biomarkers of intestinal leak with sarcopenia in various stages of CKD. We recruited 61-76-year-old male controls and patients with various stages of CKD (n = 36-57/group) for measuring plasma lipopolysaccharide-binding protein (LBP) and zonulin (markers of intestinal leak), handgrip strength (HGS), skeletal mass index (SMI), and gait speed (markers of sarcopenia), and short physical performance battery (SPPB; marker of physical capacity). CKD stages 4 and 5 were associated with lower HGS, SMI, gait speed, and cumulative SPPB scores and a higher sarcopenia prevalence than controls and patients with CKD stages 1 and 2 (all p < 0.05). CKD patients (stages 1 and 2) had elevated plasma zonulin and LBP when compared with CKD stages 4 and 5. Plasma zonulin and LBP exhibited significant correlations with renal function, HGS, gait speed, SPPB scores, and oxidative stress markers in CKD stages 4 and 5 (all p < 0.05). However, similar relations were not found in early CKD. Collectively, intestinal leak may be contributing to sarcopenia and physical disability in the advanced stages of CKD.
1. Crystalline form II of cabergoline. 2. Crystalline form II of cabergoline according to claim 1 which is anhydrous, non-solvated and has a percentage purity greater than 85%. 3. Crystalline form II of cabergoline according to claim 1 which is anhydrous, non-solvated and has a percentage purity greater than 98%. 4. Crystalline form II of cabergoline having the XRD powder pattern of Figure 1. 5. A pharmaceutical composition which comprises an effective amount of crystalline Form II as defined in any one of claims 1 to 4 in combination with one or more pharmaceutically acceptable carriers, excipients, diluents or adjuvants. 6. A process for producing cabergoline Form II as defined in any one of claims 1 to 4, which process comprises crystallisation of the desired form II from a solution of raw cabergoline in an organic solvent at a low temperature. 7. A process according to claim 6 in which the organic solvent is a ketone, an acetal, a linear ether, an ester or a mixture thereof. 8. A process according to claim 6 or 7 in which the solvent is diethyl ether or methyl tert-butyl ether. 9. A process for producing cabergoline Form II as defined in any one of claims 1 to 4, which process comprises subjecting a mixture of cabergoline forms I and II in a solvent at a temperature below about 30 degree C to a slurry procedure. 10. A process according to claim 9 in which the solvent is diethyl ether or n-hexane.
To examine how risk for colorectal cancer (CRC) is related to the microbes that inhabit the distal human intestine (the microbiota), we have proposed a large study that compares characteristics of the fecal microbiota in CRC patients and controls in the Shanghai population. In advance of that, we are proposing a small pilot study with the following two objectives: 1) determine participation rates among Shanghai adults, age 50-74 who are positive by fecal immunochemical test (FIT+); and 2) determine the suitability of fecal specimens provided by the participants for microbiome analyses. Each of two Shanghai community health centers, where CRC screening is ongoing, will recruit 25 FIT+ participants (half male; half age 50-64, half age 65-74). Each of the 50 participants will provide informed consent, brief questionnaire data, blood plasma and buffy coat, a urine specimen, and four samples of one stool, which will be frozen. Complete blood count and plasma glucose, cholesterol, and creatinine levels will be determined in real time and returned to the participant. Each participant s plasma, buffy coat, urine, and one pair of fecal samples will be stored frozen for future genetic or other assays. DNA will be extracted from the second pair of fecal samples from each participant (n=100 vials), amplified for 16S rRNA genes, and sequenced to determine fecal microbiome profiles. Participation will be deemed unsatisfactory if participation is \<30% overall (95% confidence interval 17% - 43% for N=50 participants), or if there are \<20 male, female, younger, or older participants. Specimen quality will be deemed unsatisfactory if the intraclass correlation coefficient (ICC) is \<0.70 (95% confidence interval 0.53 0.82 for N=50 paired vials) for the Shannon index estimate of microbiome alpha diversity. As amended, the two community health centers will recruit up to 600 additional adults presenting for CRC screening, irrespective of FITstatus, who will be asked to provide saliva as well as the other specimens.
Current treatment options for postoperative pain in older adults tend to be concentrated on opioid and opioid-sparing medications, which carry an increased risk of complications in older adults. One non-pharmacological intervention to manage acute pain that has recently emerged in the healthcare setting is virtual reality (VR).VR engages the user through various technological equipment with differing degrees of immersion and has demonstrated efficacy in decreasing acute pain in various clinical settings, such as burn wound care treatment and adult and pediatric medical procedures. However, there is a scarcity of research examining VR as an adjunct treatment in older adult populations. Therefore, this study aims to examine the acceptability and efficacy of VR as a possible adjunct to current postoperative pain management regimens in older surgical patients undergoing inpatient elective major operations.

The overarching hypotheses are: 1. Older adults who receive immersive VR will demonstrate immediate improvements in self-reported pain intensity, anxiety, and state of relaxation from pre-intervention levels, and 2. Older adults will consider their VR experience positive, effective, and practical in the inpatient postoperative period, with negligible side effects reported.

The VR intervention will consist of the use of the REAL System i-Series VR head-mounted display (HMD) with built-in audio purchased from Penumbra, Inc. The i-Series is a gazed-controlled and fully immersive VR headset preloaded with immersive environments that promote positive distraction and relaxation through interactive experiences. These VR experiences include mindful meditation, travel, various nature scenes, and game experiences. After written informed consent is obtained and baseline questionnaires have been completed, enrolled participants will be given the option to utilize the REAL i-series HMD during their postoperative inpatient stay on the medical-surgical unit, as early as the first day following surgery (postoperative day \[POD 1\] 1) up through POD 3, unless discharge occurs first. The VR intervention will be offered to all participants at least once (for a maximum use of up to twice daily) up to six times. Each VR session will last up to no longer than 30 minutes. The length of each session will be dependent on the participant's selection of the virtual environment. Pain, anxiety, state of relaxation, and side effects will be measured before and after each VR session using pre-post questionnaires (Numeric rating scale for pain and relaxation and the Spielberger State Anxiety Inventory for anxiety). After each VR session, participants will be asked about side effects. All participants will be asked to complete the System Usability Scale (SUS) questionnaire before discharge. Additionally, a convenience sample of up to 15 patients from diverse groups will be asked about their experience with VR through a one-time one-on-one, 15-minute qualitative semi-structured interview \& a user satisfaction survey.
PURPOSE: To assess the success of the short-term location of the heavy silicone oil (Densiron 68, HSO) as endotamponade after pars plana vitrectomy for rhegmatogenous complex retinal redetachment.
METHODS: Consecutive, retrospective, nonrandomized, pilot study was conducted. Twenty-two eyes of 22 patients with complex inferior retinal redetachment previously tamponade with gas (SF6 or C3F8) or 1000 cSt standard silicone oil (SSO) were selected. All were treated with HSO endotamponade, and its removal was performed after 1 month. The main outcomes were best-corrected visual acuity and postoperative complications after the HSO removal.
RESULTS: Of the 22 eyes, 10 were treated with SSO endotamponade, 3 with fluorinated gas 14% C3F8, and 9 with 20% SF6 at first surgery. In all eyes, a complex inferior retinal redetachment was observed after the first surgery, in 1 month to 3 months after silicone oil removal or gas endotamponade introduction. In 10 eyes, the proliferative vitreoretinopathy (Grade B or C 1-3) was found. The main best-corrected visual acuity before HSO removal was 0.55 ± 0.20 the logarithm of the minimum angle of resolution (range 0.4-0.7) and after the HSO removal, it was 0.32 ± 0.29 the logarithm of the minimum angle of resolution (0.1-0.4). Among the postoperative complications, only in four eyes the macular edema was found (medically resolved), in four eyes an increase of intraocular pressure, and none of these developed the epiretinal membrane.
CONCLUSION: The main purpose of this study is to establish a short-term HSO endotamponade in eyes with complex retinal detachment recurrences, reducing the possible postoperative complications and having a better prognosis for visual acuity outcomes.
In the present invention, there is disclosed a single-chain multifunctional polypeptide specific for CD19 and CD3 antigens. This polypeptide contains (a) a first domain comprising a binding site of an immunoglobulin chain or an antibody specifically recognizing the CD19 antigen; (b) a second domain comprising a binding site of an immunoglobulin chain or an antibody specifically recognizing the CD3 antigen of human T-cells; where said domains are arranged in a sequence ViLCD19-ViHCD3-ViLCD3. This polypeptide can contain at least one other domain, advantageously with predefined function. Furthermore, there are described polynucleotides, host cells transferred therewith and their use in preparation of said polypeptide. Further the invention discloses agents, preferably pharmaceutical and diagnostic agents, containing these polypeptides, polynucleotides or vectors; use of aforesaid polypeptides, polynucleotides and vectors for preparation of pharmaceutical agents for immunotherapy, preferably therapy against B-lymphocytes malignancies such as non-Hodgkin lymphoma. The invention discloses also method for identification of activators or activation inhibitors or T-lymphocytes stimulation.
PURPOSE:To obtain the titled extract economically in an industrial scale, by concentrating the decocted liquid of a gramineous plant having various drug actions, mixing the liquid with a medium effective for raising the boiling point to obtain the first concentrated extract, increasing the viscosity of the original concentrated liquid with the first extract, and concentrating the obtained mixture to afford the final concentrated extract. CONSTITUTION:Decocted and concentrated liquid of a gramineous plant such as rice, barley, adlay, etc. is added with a medium effective for raising the boiling point (e.g., 0.1% sodium carbonate, superheated steam, etc.), and heated at an effective temperature lower than the caramelization temperature (200 deg.C), e.g. at 120-160 deg.C for 6-12hr to obtain the first concentrated extract. A concentrated extract prepared by the same process is added with a small amount of the above first concentrated extract to raise the viscosity, and the mixture is heated, added with hot water, and boiled. The supernatant liquid is separated and again concentrated by boiling to obtain the final concentrate. A large amount of a concentrated extract can be prepared effectively, with a simple procedure, without using a particular solvent, by raising the viscosity of the decocted solution, and concentrating the solution at a high temperature.
The invention provides an application of an isodaphnetin compound in the preparation of antidiabetic medicines. The structural formula of isodaphnetin is shown in the specification. According to the invention, a high-sugar high-fat forage combined with a small dosage of streptozotocin (STZ) is applied to establish type 2 diabetes rat models, and male SD adult rats can be fed with the high-sugar high-fat forage for 1 month to induce insulin resistances and injected with a small dosage of the STZ 25mg each kilogram in an abdominal cavity mode to establish the type 2 diabetes rat models; and said given medicine is injected in the abdominal cavity mode, and blood sugar, serum insulin, glucagon, mental states, body weights, water drinking amounts, appetites and the like of the rates are detection indexes. Experiment results show that after treating with isodaphnetin, the blood sugar values and the serum insulin levels of the type 2 diabetes rat models are obviously decreased (P is less than 0.01), and there are no obvious blood sugar value differences among rats having obvious increased insulin levels (P is greater than 0.05). So, isodaphnetin can be used for preparing the antidiabetic medicines. The medicine is a medicinal composition comprising isodaphnetin as an active compound and a medicinal carrier.
<P>PROBLEM TO BE SOLVED: To provide a device for producing water having activating action which can supply a user with water having activating action by producing the water having activating action effective in many uses and is easily maintained by the user.  <P>SOLUTION: This device for producing the water having activating action comprises lighting fitting 10, a transmitting member 14 through which light 12 emitted from the lighting fitting 10 passes, a water flowing member 18 provided with a reflection mirror 16 on a wall for causing water flow, and a housing tank 20 for housing water discharged from the water flowing member 18. Minerals 26 that receive light and emit light are provided on the top surface of the transmitting member 14, and many transparent glass beads 32 laid all over on an inner wall surface 30 are provided internally. The water flowing member 18 is formed in a funnel shape and provided with a supply pipe 38. When the lighting fitting 10 is turned on and water 42 is supplied to the water flowing member 18, the water is caused to flow spirally on the reflection mirror 16 while receiving the light 12 emitted from the transmitting member 14. In such a case, the water 42 absorbs light energy and resonant vibrations caused by water molecules make water clusters small. The water 48 with smaller clusters is discharged to the outside from a discharge port 46 of the water flowing member 18.  <P>COPYRIGHT: (C)2003,JPO
The invention relates to the technical field of medicine, in particular to a powder coated folic acid and a preparation method thereof. The powder coated folic acid is prepared from folic acid and an appropriate coating material by a powder coating technology. The weight ratio of the coating material to folic acid is 0.03:1.0-0.6:1.0. The invention also discloses a preparation method of the powder coated folic acid. The stable powder coated folic acid provided by the invention not only has good light stability, but also shows good humidity stability. In actual production application, the powder coated folic acid provided by the invention also has good powder mechanical characteristics, is easy for uniform mixing with other materials in an industrialization process, is applicable to but not limited to large-scale processing and production of food, health care products and drugs, and the final product also has superior dissolution behavior while maintaining good stability, and is conducive to absorption of folic acid by the body.
PURPOSE:A cosmetic containing purified babassu oil capable of imparting a light feeling without stickiness and acting as an excellent emollient agent. CONSTITUTION:A cosmetic composition containing purified babassu oil. The babassu oil is a nondrying oil obtained from the nucleus of a fruit of a plant babassu palm of the family Arecaceae and consists mainly of triglyceride of an 8-18C fatty acid. Since the number of carbon atoms is relatively small, the babassu oil is a liquid or soft and ideal cosmetic raw material though the degree of unsaturation is low. Crude purified babassu oil obtained by subjecting babassu oil to distillation, oxidative bleaching, adsorption, etc., is dissolved in a nonpolar solvent, passed through an adsorption column to adsorb and remove polar impurities and the nonpolar solvent is distilled away to afford the aimed purified babassu oil having highly improved peculiar smell, hue and particularly stability to oxidative deterioration with time. The above-mentioned cosmetic has high emollient property and good feeling of use with slight oiliness.
Senescence of activated hepatic stellate cells (HSCs) is crucial for the regression of liver fibrosis. However, impaired immune clearance can result in the accumulation of senescent HSCs, exacerbating liver fibrosis. The activation of the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway is essential for both senescence and the innate immune response. Additionally, the specific delivery to activated HSCs is hindered by their inaccessible anatomical location, capillarization of liver sinusoidal endothelial cells (LSECs), and loss of substance exchange. Herein, we propose an antifibrotic strategy that combines prosenescence with enhanced immune clearance through targeted delivery of manganese (a cGAS-STING stimulator) via albumin-mediated transcytosis, specifically aimed at inducing senescence and eliminating activated HSCs in liver fibrosis. Our findings demonstrate that only albumin efficiently transfers manganese to activated HSCs from LSECs via transcytosis compared to liposomes, resulting in significant antifibrotic effects in vivo while exhibiting negligible toxicity.
A system and method for updating medical records of a third-party medical provider over a computer network is herein disclosed. The system can comprise a server memory, and a server processor. The server memory that stores a client profile, a session information, and a virtual care website. The session information related to each of the client profile. The server processor that according to instructions from the virtual care website captures the session information between a physician and a patient through a virtual chat application. The patient related with the client profile. Moreover, according to the instructions from the virtual care website queries a third-party medical provider to match patient information with said patient. The patient information is associated with one or more medical records. Additionally, according to the instructions from the virtual care website stores the session information under the medical records of the patient that matches the client profile.
Tracheoesophageal fistula (TEF) with or without esophageal atresia (EA) results from maldevelopment of the trachea and esophagus during maturation of the primitive foregut. EA/TEF commonly presents shortly after birth because of increased oral secretions and the inability to advance a nasogastric or orogastric tube to the proper depth. Given that prenatal diagnosis is uncommon and early intervention is important to reduce morbidity and mortality risk, early recognition and diagnosis are imperative. We present a case series of two neonates diagnosed with EA/TEF, type "C" and type "E," born at low-acuity centers, who required transport to a tertiary center for surgical support. The pathophysiology as well as types of TEFs, symptomology, stabilization goals, corrective treatment, and long-term implications will be examined. Finally, the educational needs of parents and caregivers will be discussed.
Exploration of medicines for efficient and safe management of metabolic-associated fatty liver disease (MAFLD) remains a challenge. Obeticholic acid (OCA), a selective farnesoid X receptor agonist, has been reported to ameliorate injury and inflammation in various liver diseases. However, its clinical application is mainly limited by poor solubility, low bioavailability, and potential side effects. Herein a hepatic-targeted nanodrugs composed of OCA and cholesterol-lowering atorvastatin (AHT) with an ideal active pharmaceutical ingredient (API) content for orally combined treatment of MAFLD is created. Such carrier-free nanocrystals (OCAHTs) are self-assembled, not only improving the stability in gastroenteric environments but also achieving hepatic accumulation through the bile acid transporter-mediated enterohepatic recycling process. Orally administrated OCAHT outperforms the simple combination of OCA and AHT in ameliorating of liver damage and inflammation in both acetaminophen-challenged mice and high-fat diet-induced MAFLD mice with less systematic toxicity. Importantly, OCAHT exerts profoundly reverse effects on MAFLD-associated molecular pathways, including impairing lipid metabolism, reducing inflammation, and enhancing the antioxidation response. This work not only provides a facile bile acid transporter-based strategy for hepatic-targeting drug delivery but also presents an efficient and safe full-API nanocrystal with which to facilitate the practical translation of nanomedicines against MAFLD.